کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2774994 | 1152303 | 2016 | 6 صفحه PDF | دانلود رایگان |
BackgroundBreast cancer stem cells (BCSCs) play essential roles in tumor metastasis and contribute to remarkably negative clinical outcomes. Recently, aldehyde dehydrogenase (ALDH) and CD44 positivity (ALDH+/CD44+) was identified as a marker of BCSCs in vitro/in vivo studies. The aim of this study was to evaluate the prevalence of ALDH+/CD44+ cells in breast cancer and the association of these two markers with clinicopathological features and clinical outcomes.Materials and methodsWe investigated the prevalence of ALDH1A3+/CD44+ cells in a cohort of 144 formalin-fixed, paraffin-embedded (FFPE) breast cancer tissues. The tissues were stained for ALDH1A3 and CD44 by single and dual immunohistochemistry (dIHC). The associations among the prevalence of ALDH1A3+/CD44+ cells, the clinicopathological features and the clinical outcomes of the patients were also analyzed.ResultsALDH1A3+/CD44+ cells were present in 39 patients (27.1%). By the Mann–Whitney U test, the Pearson Chi-square test or Fisher's exact test, it was demonstrated that the prevalence of ALDH1A3+/CD44+ cells was closely correlated with larger tumor size (p = 0.001), nodal metastasis status (p = 0.043), more advanced clinical stage (p = 0.021) and distant metastasis after initial surgery (p = 0.001). In a univariate survival analysis, the presence of ALDH1A3+/CD44+ tumor cells had a significant negative association with both disease-free survival (DFS) and overall survival (OS) (pDFS < 0.001; pOS < 0.001). The negative clinical outcomes in ALDH1A3+/CD44+ tumors were further confirmed by a multivariate analysis using Cox proportional hazard models (pDFS < 0.001, HR = 3.155; pOS = 0.001, HR = 3.193). This was also true with respect to the clinical treatment regimens of chemotherapy (pDFS < 0.001; pOS = 0.001), radiotherapy (pDFS = 0.004; pOS = 0.004), and endocrine therapy (pDFS < 0.001; pOS < 0.001).ConclusionIn summary, our results indicate that the prevalence of ALDH1A3+/CD44+ tumor cells in breast cancer is significantly associated with worse prognostic factors and favors a poor prognosis.
Journal: Experimental and Molecular Pathology - Volume 100, Issue 1, February 2016, Pages 145–150